Stifel Nicolaus Initiates Coverage on Beta Bionics (NASDAQ:BBNX)

Stock analysts at Stifel Nicolaus initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report issued on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 21.54% from the stock’s previous close.

BBNX has been the subject of a number of other research reports. Baird R W raised Beta Bionics to a “hold” rating in a research report on Thursday. Robert W. Baird assumed coverage on shares of Beta Bionics in a report on Thursday. They set a “neutral” rating and a $20.00 target price for the company. LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research note on Thursday. They issued a “neutral” rating and a $20.00 price target on the stock. Leerink Partners started coverage on Beta Bionics in a report on Monday. They issued an “outperform” rating and a $28.00 price objective for the company. Finally, Piper Sandler started coverage on Beta Bionics in a research report on Monday. They set an “overweight” rating and a $26.00 price target for the company. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and an average price target of $23.80.

Beta Bionics Stock Performance

BBNX stock opened at $20.57 on Monday. Beta Bionics has a fifty-two week low of $20.57 and a fifty-two week high of $24.50.

Insider Buying and Selling

In related news, insider Mike Mensinger purchased 33,350 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were bought at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now directly owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.